Major Depression Disorder clinical trials

Explore recruiting major depression disorder clinical trials.

Recruiting major depression disorder studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Major Depression Disorder trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Compare the Anti-Depressive Efficacy and Safety of Samyr® Tablet versus Placebo Tablet on top of Adjunctive Antidepressant Treatment in Patients with Major Depression Disorder with Mild to Moderate Symptoms

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Ketamine maintenance treatment for depression: A multicenter open-label randomized controlled trial

Norway

Therapeutic exploratory (Phase II) EU CTIS Study details

Comparison between esketamine nasal spray versus aripiprazole, both in combination with an antidepressant, in the refractory major depression disorder (RMDD) in elderly patients (CESAR)

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

AIDA-DEP - Accelerated Intermittent theta-burst stimulation with D-cycloserine Augmentation for DEPression - a multicenter, randomized, placebo-controlled, double-blind clinical trial

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-center Study to Compare the Anti-Depressive Efficacy and Safety of Samyr® IM versus Placebo IM as an Enhancer Adjunctive to Antidepressant Treatment in Major Depression Disorder Patients Who have not Experienced Sufficient Symptoms Improvement Despite Antidepressant Treatment

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Major Depression Disorder trials by city

Major Depression Disorder in Toronto Major Depression Disorder in Vancouver Major Depression Disorder in Montreal Major Depression Disorder in Calgary Major Depression Disorder in Edmonton Major Depression Disorder in Ottawa Major Depression Disorder in Winnipeg Major Depression Disorder in Quebec City Major Depression Disorder in Hamilton Major Depression Disorder in Kitchener Major Depression Disorder in London Major Depression Disorder in Halifax Major Depression Disorder in New York Major Depression Disorder in Los Angeles Major Depression Disorder in Chicago Major Depression Disorder in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease